CRISPR Therapeutics AG (CRSP) FCF Margin (2016 - 2026)

CRISPR Therapeutics AG has disclosed FCF Margin across 11 years of filings, most recently posting 826.5% for Q2 2026.

• In Q2 2026, FCF Margin rose 1195343.0% year-over-year to 826.5%; the TTM figure through Jun 2026 stood at 2772.74% (down 191711.0% YoY), while the FY2025 annual figure was 9855.5%, down 946778.0% from the prior year.
• FCF Margin came in at 826.5% for Q2 2026 at CRISPR Therapeutics AG, up from 7503.5% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 21633.13% in Q1 2024 to a low of 1991983.33% in Q4 2022.
• Average FCF Margin over 5 years is 134418.59%, with a median of 9528.46% recorded in 2025.
• Year-over-year, FCF Margin plunged 199124513 bps in 2022 and jumped 199193522 bps in 2023.
• Over 5 years, FCF Margin stood at 1991983.33% in 2022, then surged by 100 bps to 48.12% in 2023, then plunged by 193 bps to 140.89% in 2024, then plunged by 7546 bps to 10771.99% in 2025, then soared by 92 bps to 826.5% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 826.5% in Q2 2026, 7503.5% in Q1 2026, and 10771.99% in Q4 2025.